Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4283 - Phase II Monotherapy Efficacy of Cancer Metabolism Targeting SM-88 in Heavily Pre-Treated PDAC Patients.

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

Allyson Ocean

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

A. Ocean1, M. Noel2, A. Wang-Gillam3, S. Chawla4, V. Chung5, S. Pant6, R. Korn7, G. Del Priore8, V. Picozzi9

Author affiliations

  • 1 Medical Oncology, Weill Cornell Medical College, 10021 - New York/US
  • 2 Medical Oncology, University of Rochester Cancer Center, 14642 - Rochester/US
  • 3 Gastrointestinal Oncology Program, Division Of Oncology, Washington University School of Medicine, 63110 - St. Louis/US
  • 4 Medical Oncology, Sarcoma Oncology Research Center, 90403 - Santa Monica/US
  • 5 Medical Oncology, City of Hope, 91010 - Duarte/US
  • 6 Investigational Cancer Therapeutics, MD Anderson Cancer Center, Huston/US
  • 7 -, Imaging Endpoints, Scottsdale/US
  • 8 Cmo, Tyme Inc, 10004 - New York/US
  • 9 Medical Oncology, Virginia Mason Medical Center, 98101 - Seattle/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4283

Background

SM-88 (D,L-alpha-metyrosine; racemetyrosine [USAN]) is a relatively non-toxic, targeted therapy based on the Warburg Effect. It may be well suited for pancreas cancer because of its ability to penetrate tumors and tolerability in compromised patients.

Methods

Subjects progressed on at least one line of chemotherapy were randomized to receive either 460 mg/d or 920 mg/d single agent SM-88 administered with low doses of methoxsalen, phenytoin, and sirolimus (MPS) in the dose selecting stage of this trial. The primary endpoint is response rate by BICR.

Results

As of April 2019, 49 subjects with stage IV pancreatic ductal adenocarcinoma with radiographically documented progressive disease were enrolled and randomized. Mean age was 66 (45 – 85); median of 2 prior lines (1 – 5+); baseline median CA19.9 was 2,674 (0.8 – 651,696). There were 22 disease related SAEs before drug treatment, including 6 Grade 5 events. SM-88 was well tolerated with only four treatment-related Grade 3/4 adverse events in two subjects (and no treatment-related Grade 5 events). 94% of treated subjects (46/49) experienced a total 365 AEs, with only 17% (63/365) at least possibly treatment related. CTCs at baseline were detected in 100% (mean 138 cells/4 ml) and fell in 79% (23/29) evaluable subjects from 153 to a nadir of 54 cells/4 ml (median reduction 63% [18% - 100%]). 12% (4/33) evaluable subjects showed CA19.9 declines (-8% to –97% decline within 3 months), three of which also showed CTC declines. Subjects have remained on treatment a median of 6.9 wks (1.7 – 23.1). While progressive upon entry, 21% (8 of 38 evaluable subjects) displayed stable disease or better at 2 months or beyond. Of the 38 evaluable subjects, 42% (16/38) were alive at 4 months post randomization, and 24% (9/38) were alive at 6 months, which parallels carry over effect previously observed with SM-88. EORTC QLQ-C30, -PAN26, and correlative assays were obtained including leptin, genomics, and NLR.

Conclusions

SM-88 demonstrated unconfirmed monotherapy effect with no meaningful toxicity in a preliminary assessment of this ongoing trial. With additional follow up, dose and patient populations will be selected for expansion.

Clinical trial identification

NCT03512756.

Editorial acknowledgement

Legal entity responsible for the study

Tyme Inc.

Funding

Tyme Inc.

Disclosure

A. Ocean: Advisory / Consultancy: Tyme Inc. M. Noel: Advisory / Consultancy: Tyme Inc. A. Wang-Gillam: Advisory / Consultancy: Tyme Inc. S. Pant: Advisory / Consultancy: Tyme Inc. G. Del Priore: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Tyme Inc. V. Picozzi: Advisory / Consultancy: Tyme Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.